問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

  • 0

    Total Beds

  • 0

    Total Doctors

  • 235New Taipei CityJhonghe

Recruiting Trial

224Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

419Cases

2019-09-01 - 2022-08-31

Phase I

A PHASE 1 DOSE FINDING/EXPANSION STUDY OF HLX55, A MONOCLONAL ANTIBODY TARGETING TYROSINEPROTEIN KINASE MET (C-MET) IN PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY

  • Condition/Disease

    solid tumor

  • Test Drug

    HLX55

Participate Sites
4Sites

Recruiting4Sites

2017-01-01 - 2020-06-30

Phase II

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects with Diabetic Foot Ulcers

  • Condition/Disease

    Diabetic foot ulcers，DFUs

  • Test Drug

    ENERGI-F703 GEL

Participate Sites
7Sites

Terminated7Sites

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄
Taipei Medical University Hospital

Division of Hematology & Oncology

2011-07-01 - 2013-12-31

Phase III

A prospective, randomized, double-blind trial comparing the long-acting basal insulin analogue LY2963016 and Lantus® in adult patients with type 2 diabetes

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
8Sites

Terminated8Sites

2012-03-01 - 2014-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2012-03-30 - 2015-11-06

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-03-01 - 2021-06-30

Phase III

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2017-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2016-12-31 - 2023-12-31

Phase III

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

  • Condition/Disease

    Prodromal Alzheimer's Disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated9Sites

2019-04-01 - 2022-12-15

Phase III

A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-3)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

1 35 36 37 38 39 42
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB